Tag: evaluating
Nanobiotix announces that it has completed the dose escalation portion of the Phase 1 study evaluating NBTXR3
By Claude Leguilloux Published on 04/03/2024 at 7:22 a.m. (Boursier.com) — Nanobiotix a French biotechnology company in…
Inventiva announces the resumption of screening in the Phase III clinical study, NATiV3, evaluating lanifibranor in NASH – 03/07/2024 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), March 7, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
TotalEnergies is evaluating its controversial project in Uganda-Tanzania – 01/04/2024 at 10:23
TotalEnergies TTEF.PA said Thursday that it had entrusted former Beninese Prime Minister Lionel Zinsou with a mission to evaluate the land acquisition program carried out as part of its controversial…
TotalEnergies is evaluating its controversial project in Uganda-Tanzania – 01/04/2024 at 10:29
TotalEnergies headquarters TotalEnergies said Thursday that it had entrusted former Beninese Prime Minister Lionel Zinsou with a mission to evaluate the land acquisition program carried out as part of its…
OSE Immunotherapeutics and the Nantes University Hospital Center present a positive interim analysis of the Phase 1/2 FIRsT clinical trial evaluating FR104/VEL-101 immunotherapy in kidney transplantation – 11/12/2023 at 07:30
At the annual congress of the Société Francophone de Transplantation Supported by the European Society of Organ Transplantation (ESOT) Nantes, France – December 11, 2023, 7:30 a.m. – OSE Immunotherapeutics…
MaaT Pharma presents positive results for MaaT013, its most advanced drug candidate, at ASH 2023 and details the ongoing Phase 2b trial evaluating MaaT033 – 11/12/2023 at 07:38
MaaT Pharma presents positive results for MaaT013, its most advanced drug candidate, at ASH 2023 and details the ongoing Phase 2b trial evaluating MaaT033 • Positive efficacy results from 111…
MaaT Pharma: treatment of a first patient in the randomized Phase 2b clinical trial evaluating MaaT033 in patients receiving allo-HSCT
By Claude Leguilloux Published on 06/11/2023 at 08:01 a.m. Photo credit © Boursier.com (Boursier.com) — MaaT Pharmaa late-stage…
Abionyx: positive results from the Racers trial evaluating its product CER-001 – 11/02/2023 at 6:18 p.m.
(AOF) – Abionyx announces the complete results of the RACERS phase 2 clinical trial evaluating CER-001, an apoA-I-based therapy for the treatment of sepsis, during the presentation of a poster…
OPM announces positive interim results from its phase 1 study evaluating OPM-101 in healthy volunteers
By Hector Chaunu Published on 02/10/2023 at 6:48 p.m. (Boursier.com) — Oncodesign Precision Medicine, a biopharmaceutical company specializing…
A directive which “offers companies a coherent set of recommendations for evaluating, measuring and reporting their impacts on sustainability issues”
Lhe European Commission has published the July 31 a first application text (“delegated act”) of its directive on the publication of non-financial information of companies (“Corporate Sustainability Reporting Directive”, CSRD).…
PHARNEXT: The latest results from CMTMe, a digital study evaluating the lifestyle of patients with Charcot-Marie-Tooth diseases (CMTs), will be presented at the 2023 Annual Meeting of the Peripheral Nerve Society (‘PNS’) – 14/ 06/2023 at 08:30
PARIS, France, June 14, 2023 at 8:30 a.m. (CET) – Pharnext SA (FR001400GUN7 – ALPHA) (the “Company”), a late-stage biopharmaceutical company developing new therapies for neurodegenerative diseases with no satisfactory…
OSE Immuno: end of patient recruitment in the phase 2 clinical trial evaluating Tedopi in advanced pancreatic cancer
By Alexandra Saintpierre Published on 05/24/2023 at 6:19 p.m. (Boursier.com) — OSE Immunotherapeutics SA announces the end…